Following negative top-line results from the Phase III TROPiCS-04 study, shares in Gilead Sciences (Nasdaq: GILD) have fallen 3% in after-hours trading.
The study is comparing the first-in-class Trop-2-directed antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) with chemotherapy, in people with advanced or metastatic bladder cancer.
People in the trial had already been treated with platinum-containing chemotherapy and a checkpoint blocker.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze